Working… Menu

Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke (CANNASTROKE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03379857
Recruitment Status : Recruiting
First Posted : December 20, 2017
Last Update Posted : June 13, 2019
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:

Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects.

There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

Condition or disease Intervention/treatment Phase
Stroke Cannabis Use Other: Drug urinal test Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Cannabis User
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke
Actual Study Start Date : January 11, 2018
Estimated Primary Completion Date : January 11, 2025
Estimated Study Completion Date : January 11, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Arm Intervention/treatment
Cannabis User Other: Drug urinal test
Non Applicable
Other Names:
  • Magnetic Resonance Imaging
  • Computerized Tomography Scan
  • Transcranial Doppler Ultrasound

Primary Outcome Measures :
  1. Evaluation Cannabis use [ Time Frame: 12 months ]
  2. Reversible vasoconstriction on medical imaging of intracranial arteries at different moment [ Time Frame: 12 months. ]
    medical imaging of intracranial arteries will show new stenoses (topography, number, evolution), and new ischemic or cerebral haemorrhagic lesions

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject between 18 and 45 years old
  • Stroke confirmed by medical imaging
  • Written informed consent (subject, nearby or emergency procedure)
  • Subject affiliate to a local healthcare insurance office
  • For female of childbearing potential, an adequate contraceptive measur

Exclusion Criteria:

  • Subject with psychiatric disorder, unable to understand the study or cooperate
  • Subject under guardianship or forfeiture of liberty
  • Pregnant or breastfeeding woman
  • Subject in period of exclusion due to another study or still in follow-up of an interventional study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03379857

Layout table for location contacts
Contact: Valérie WOLFF, MD +33 3 88 12 86 06

Layout table for location information
Chu Jean Minjoz Recruiting
Besancon, France, 25030
Contact: Thierry MOULIN    +33 3 81 66 84 38   
Principal Investigator: Thierry MOULIN         
Unite Neuro-Vasculaire Recruiting
Colmar, France, 68024
Contact: Francis VUILLEMET    +33 3 89 12 41 50   
Principal Investigator: Francis VUILLEMET         
Chu Bocage Recruiting
Dijon, France, 21079
Contact: Yannick BEJOT    +33 3 80 29 37 53   
Principal Investigator: Yannick BEJOT         
C.H. G. Muller Recruiting
Mulhouse, France, 68070
Contact: Eric SCHLUCK    +33 3 89 64 61 81   
Principal Investigator: Eric SCHLUCK         
Hopital Central Recruiting
Nancy, France, 54035
Contact: Sébastien RICHARD    +33 3 83 85 22 56   
Principal Investigator: Sébastien RICHARD         
Les Hôpitaux Universitaires de Strasbourg Recruiting
Strasbourg, France, 67098
Contact: Valérie WOLFF, MD    33 3 88 12 86 06   
Principal Investigator: Valérie WOLFF, M         
Sub-Investigator: Valérie LAUER         
Sub-Investigator: Simona SABAU PHILIPPI         
Sub-Investigator: Mihaela DIACONU         
Sub-Investigator: Danièla BINDILA         
Sub-Investigator: Lelyzaveta ZINCHENKO         
Sub-Investigator: Véronique QUENARDELLE         
Sub-Investigator: Stéphane KREMER         
Sponsors and Collaborators
University Hospital, Strasbourg, France
Layout table for investigator information
Principal Investigator: Valérie WOLFF, MD Hôpitaux Universitaires de Strasbourg

Layout table for additonal information
Responsible Party: University Hospital, Strasbourg, France Identifier: NCT03379857     History of Changes
Other Study ID Numbers: 6640
First Posted: December 20, 2017    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders